{
  "docId": "019dd923-5e88-73ef-bd5c-f6fdd8f57895",
  "docSlug": "3a892393f72c1ff5",
  "documentTitle": "2019 Air Street Capital The State of AI Report 2019",
  "authorId": "AirStreetCapital",
  "authorName": "Nathan Benaich and Ian Hogarth",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "vc_research",
  "sourceTypeLabel": "VC research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 81,
  "pageCount": 136,
  "prevPage": 80,
  "nextPage": 82,
  "slideType": "case_study",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide highlights the business model of AI drug discovery startups (Atomwise and Exscientia) through partnerships with Charles River and Celgene.",
  "elementsJson": [
    "logo_grid",
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5c-f6fdd8f57895/81",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5c-f6fdd8f57895",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5c-f6fdd8f57895.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5c-f6fdd8f57895#slide-81",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Atomwise projects that the total potential value of the royalties to Atomwise with success in all projects could exceed US$2.4 billion.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-41ac-7180-a805-6e76d8f98837",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "image",
      "text": "Exscientia + Celgene logos",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e79228e-90fc-489d-a9d8-f59345ab9790",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "image",
      "text": "Atomwise + Charles River logos",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba9aa17d-9216-4e06-ba56-425ea607886b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Potential royalty value: $2.4 billion",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-41ac-7180-a805-724f9cc557fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "Exscientia, a startup based in Scotland, claim to be able to reduce the time to discover pre-clinical drug candidates by at least 75%. Their partnership with Celgene, a global pharma company focused on cancer and inflammatory disorders, includes an initial $25M upfront payment with Exscientia being eligible to receive significant milestone and royalty payments based on the success of the programme and future sales.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc5b194b-ad01-4346-804a-76e570ac181c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Atomwise, an SF-based startup, uses convolutional neural networks to predict the binding capacity of small molecule drugs to target proteins of interest. This partnership with Charles River Laboratories will support the contract research organisation's hit discovery, hit-to-lead, and lead optimization efforts. Atomwise receives technology access fees, milestone-based payments and royalties from clients. Atomwise projects that the total potential value of the royalties to Atomwise with success in all projects could exceed US$2.4 billion.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f72824ab-0f93-473f-9e9b-ebca45874dc7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "title",
      "text": "Healthcare: Pharma companies partner with AI-driven drug development companies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0af4a6f-26bb-4cc9-9275-596e58356030",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "019dd95a-0fd5-7148-8ecd-904c3b49a70c",
      "evidence": "Callout cites $2.4B Atomwise royalty potential.",
      "confidence": 80
    },
    {
      "name": "Big Idea Formula",
      "slug": "big-idea-formula",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "588464b8-8106-43fd-a16c-527ca7020666",
      "evidence": "Atomwise projects that the total potential value of the royalties to Atomwise with success in all projects could exceed US$2.4 billion.",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 92,
      "from": 5,
      "beatId": "019dd95a-0682-776c-8e34-ce57e5bbe574",
      "arcName": "The Triple Take",
      "arcSlug": "triple-take",
      "beatName": "The Facts (What)",
      "beatSlug": "triple-take-the-facts-what",
      "evidence": "Definitions through Research/Talent/Industry — fact-dense case studies and benchmarks.",
      "position": 1,
      "confidence": 70,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    },
    {
      "to": 92,
      "from": 9,
      "beatId": "019dd95a-0682-776c-8e34-ddbccb391af1",
      "arcName": "Voyage and Return",
      "arcSlug": "voyage-return",
      "beatName": "The Unknown",
      "beatSlug": "voyage-return-the-unknown",
      "evidence": "Research/Talent/Industry frontiers explored.",
      "position": 2,
      "confidence": 45,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 83,
      "from": 80,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "019dd95a-07fe-70ce-8d3c-cc75c4a0b6da",
      "evidence": "FDA clearances, Atomwise $2.4B deals, nutrition prediction case studies.",
      "position": 15,
      "objective": "Stack healthcare/pharma AI deployment evidence",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 70,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}